Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
Seres Therapeutics, a leading live biotherapeutics company, has announced its participation in the Cantor Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seres Therapeutics, a leading live biotherapeutics company, has announced its participation in the Cantor Global Healthcare Conference. Eric Shaff, the company's President and CEO, will deliver a presentation on September 18, 2024, at 3:05 p.m. ET.
Investors and interested parties can access a video webcast of the presentation through the "Events and Presentations" tab on the "Investors and News" section of Seres' website. The replay will be available approximately one hour after the event and will remain accessible for 21 days.
This participation in a major healthcare conference demonstrates Seres Therapeutics' commitment to engaging with the investment community and sharing updates on their progress in the live biotherapeutics field.
Details
News Market Reaction – MCRB
The recorded move for MCRB in the trading session of this news was +4.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent Seres in a presentation on September 18, 2024 at 3:05 p.m. ET.
A video webcast of the presentation will be available under the “Events and Presentations” tab on the “Investors and News” section of Seres’ website. The replay will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic. The Company is developing SER-155, designed to prevent gastrointestinal-derived bloodstream infections, enhance epithelial barrier integrity, and induce immune tolerance responses to reduce the incidence of graft-versus-host-disease. The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. For more information, please visit www.serestherapeutics.com.
Investor and Media Contacts:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.